Nothing Special   »   [go: up one dir, main page]

Imberti et al., 2023 - Google Patents

Radiometal-Labeled Photoactivatable Pt (IV) Anticancer Complex for Theranostic Phototherapy

Imberti et al., 2023

View HTML
Document ID
10224821132931702350
Author
Imberti C
Lok J
Coverdale J
Carter O
Fry M
Postings M
Kim J
Firth G
Blower P
Sadler P
Publication year
Publication venue
Inorganic Chemistry

External Links

Snippet

A novel photoactivatable Pt (IV) diazido anticancer agent, Pt-succ-DFO, bearing a pendant deferoxamine (DFO) siderophore for radiometal chelation, has been synthesized for the study of its in vivo behavior with radionuclide imaging. Pt-succ-DFO complexation of Fe (III) …
Continue reading at pubs.acs.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Similar Documents

Publication Publication Date Title
Boros et al. Acyclic chelate with ideal properties for 68Ga PET imaging agent elaboration
Preihs et al. Recent developments in texaphyrin chemistry and drug discovery
Fazaeli et al. Development of a 68 Ga-fluorinated porphyrin complex as a possible PET imaging agent
Lima et al. Monopicolinate cyclen and cyclam derivatives for stable copper (II) complexation
Bartholomä Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography
Parrilha et al. Applications of radiocomplexes with thiosemicarbazones and bis (thiosemicarbazones) in diagnostic and therapeutic nuclear medicine
Boros et al. Macrocycle‐based hydroxamate ligands for complexation and immunoconjugation of 89zirconium for positron emission tomography (PET) imaging
Ranyuk et al. 68Ga/DOTA-and 64Cu/NOTA-phthalocyanine conjugates as fluorescent/PET bimodal imaging probes
Boros et al. Evaluation of the H2 dedpa scaffold and its cRGDyK conjugates for labeling with 64Cu
Waghorn Radiolabelled porphyrins in nuclear medicine
Wang et al. H4octox: versatile bimodal octadentate acyclic chelating ligand for medicinal inorganic chemistry
Imberti et al. Radiometal-Labeled Photoactivatable Pt (IV) Anticancer Complex for Theranostic Phototherapy
JF Calvete et al. Tetrapyrrolic macrocycles: Potentialities in medical imaging technologies
Entract et al. Development of PDT/PET theranostics: Synthesis and biological evaluation of an 18F-radiolabeled water-soluble porphyrin
Pandya et al. New bifunctional chelator for 64Cu-immuno-positron emission tomography
Choudhary et al. Octadentate oxine-armed bispidine ligand for radiopharmaceutical chemistry
Hayne et al. Rhenium and technetium complexes that bind to amyloid-β plaques
Yang et al. Synthesis of DOTA-pyridine chelates for 64 Cu coordination and radiolabeling of αMSH peptide
Derks et al. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
Price et al. Evaluation of a bispidine‐based chelator for gallium‐68 and of the porphyrin conjugate as PET/PDT theranostic agent
Buchwalder et al. Evaluation of the tetrakis (3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium (IV): thermodynamic solution studies, bifunctionalization, and in vivo assessment of macromolecular 89Zr-THPN-conjugates
Wang et al. H2 CHX hox: Rigid Cyclohexane-Reinforced Nonmacrocyclic Chelating Ligand for [nat/67/68Ga] Ga3+
Blower et al. Gallium: New developments and applications in radiopharmaceutics
Kim et al. Porphyrin-based tumor-targeting theranostic agent: Gd-TDAP
Joaqui-Joaqui et al. Catechol-based functionalizable ligands for gallium-68 positron emission tomography imaging